'Accept me': Near Ukraine front, a haven for outcasts

People living with HIV, those recovering from drug addiction, sex workers -- all are welcome to seek medical guidance and respite from stigma and solace as Russian troops advance toward Kramatorsk.
The refuge they find at Svitanok is vital during the war, when marginalised communities often feel left behind and face heightened insecurity and stigma.
"They support me here, they respect me. I just came to drink some tea. They'll treat me, I know they'll accept me," says Oleg Makaria, who is HIV-positive.
Makaria, who comes to Svitanok most days, hardly reacts to the air raid sirens once again wailing in Kramatorsk, just 20 kilometres (12 miles) from the front.
The 41-year-old jokes that he does not look his age. But he suddenly breaks down thinking about Donetsk, his home city now in Russian hands.
"I understand I can't return to Donetsk anymore. Never in my life. Probably... I'm here alone," he mutters through tears.
Moscow-backed separatists seized parts of the Donetsk region in 2014, a prelude to the Kremlin's full-scale 2022 invasion, which the UNHCR says has displaced nearly 11 million people.
The conflict disrupted treatment -- which needs to be taken daily to control HIV -- to some of the 250,000 Ukrainians estimated by UNAIDS to be living with the infection in 2020.
'I didn't break'
Advances from Russian troops have also threatened drug treatment programmes.
Moscow and its proxies have banned opioid substitution, which replaces dangerous opioids with less harmful substances such as methadone.
Approved by the United Nations and the World Health Organisation, the treatment also reduces HIV transmission as it lowers drug injections.
No one would guess looking at Natalia Zelenina, but the bright social worker sporting a red bob and bright pink lipstick spent five years in Russian custody.
She was carrying legally prescribed drugs for her replacement therapy when she was stopped by Moscow-backed separatists controlling parts of the Donetsk region in 2017.
"I realised how strong I was," the 52-year-old said.
While her colleagues campaigned to get her out, she fought to obtain treatment for her HIV.
"I survived, I endured it all. I went through it all. I didn't break," she said.
After being released to Kyiv-controlled territory in a prisoner exchange, Zelenina returned to Svitanok.
"I knew that I could only recover in a familiar atmosphere," she says.
But even in the protective bubble of Svitanok, where most workers have HIV and a drug dependency, the boom of explosions can be heard in the distance.
One employee told AFP she started consuming "just a little bit" of drugs to alleviate her anxiety –- until her colleagues helped her get clean again.
Iryna Mamalakieva arrives holding her four-year-old son Maksym, who wobbled off at any opportunity to pick dandelions on a patch of grass.
The unemployed 31-year-old former mine operator, diagnosed with HIV in 2019, relies on Svitanok for medical and legal help.
"Some people give up, some hang themselves. I knew people like that: They found out about their diagnosis, and even if they had children, they drank themselves to death and quietly went to hang themselves," she said.
'Melancholy in my soul'
The war has exacerbated stigma towards HIV-positive people and those suffering from drug addictions, counsellor Svitlana Andreieva told AFP.
"The rest of the world that's outside our doors, it tells them that they are nobody, that they're not accepted, they're not respected," she said.
Andreieva herself remembers being kicked out of hospitals and beaten up by the police because she was addicted to drugs and HIV-positive.
Then she learned law, which she shares with visitors who went through similar experiences.
"The next time they don't come with tears," she said. "They say: 'What do I need to do, which law article should I rely on?'"
But Andreieva's patience is often tested.
After an altercation with a regular, she finds a bouquet of lilacs in lieu of apologies in the office.
Hard to win over, she initially shrugs it off.
But Svitanok's workers and beneficiaries face yet another hurdle: cuts in US humanitarian aid.
Svitanok has for now survived Washington's aid freeze, but is scrambling to find alternative sources of funding for some of its many programmes, which partly rely on US money.
The uncertainty "really knocked me out of my stability", Zelenina says.
© 2025 AFP

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

France 24

2 days ago

• France 24

US approves promising preventive HIV treatment

The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injvirection, for preventing HIV infection in adults and adolescents at high risk of contracting the deadly virus. Lenacapavir proved nearly 100% effective at preventing HIV in large trials last year, raising new hope of interrupting transmission of the virus that infects 1.3 million people a year.

Euronews

2 days ago

• Euronews

What are the health risks of Israeli strikes on Iran's nuclear sites?

As the conflict between Israel and Iran intensifies, air strikes on Iran's nuclear sites could have serious health consequences across the region. Monitoring groups have not yet documented any such impact. On Monday, the International Atomic Energy Agency (IAEA), the United Nations' nuclear watchdog, said it had not identified radiation leaks as a result of Israeli strikes that began Friday and have killed hundreds of people in Iran. But that could change quickly as the attacks continue. Tedros Adhanom Ghebreyesus, chief of the World Health Organization (WHO) said Tuesday that he is worried about 'the targeting of nuclear sites, which may have immediate and long-term impacts on the environment and health of people in Iran and across the region'. Not all strikes on nuclear facilities would be the same, and an Israeli military official has said their forces plan to minimise the risk of a nuclear disaster and the consequences for civilians. 'There are gradients of risk,' Simon Bennett, who leads the civil safety and security unit at the University of Leicester in the UK and wrote a book on wartime risks to nuclear facilities, told Euronews Health. A successful attack on a live nuclear reactor would be the most devastating to human health, spreading radioactive materials that could endanger people hundreds of kilometres away. But Iran's only commercial nuclear power plant, the Bushehr plant, has not been targeted or affected by the recent attacks, according to the IAEA. Israel has targeted three key nuclear facilities: Natanz, Isfahan, and Fordo. The sites use centrifuges to enrich uranium gas, which produces the fuel that powers civilian nuclear reactors. These centrifuges would also be central to an Iranian effort to develop nuclear weapons, which European Union officials have said must not happen. Israeli strikes fully destroyed the above-ground plant at the Natanz facility, which is more than 100 miles from Tehran. The attacks also severely damaged the site's below-ground operations, which contain its centrifuges. According to the IAEA's director general Rafael Mariano Grossi, there is both 'radiological and chemical contamination' inside the Natanz facility. During an emergency meeting on Monday, Grossi said uranium isotopes may have spread within the facility. Such a leak would consist primarily of alpha particles and would pose a 'significant danger if uranium is inhaled or ingested'. Those dangers include a higher risk of cancer and damage to the kidneys, lungs, and bones. 'However, this risk can be effectively managed with appropriate protective measures, such as using respiratory protection devices while inside the affected facilities,' Grossi added. The level of radioactivity surrounding the site, meanwhile, 'has remained unchanged and at normal levels, indicating no external radiological impact to the population or the environment from this event,' Grossi said. Israel also hit a nuclear research facility in Isfahan on Friday, the IAEA said, damaging four buildings, including a uranium conversion plant. But there has been no sign of increased radiation there. Israel has been eyeing an attack on the secretive Fordo fuel enrichment site, which is where many analysts believe Iran has been working on its nuclear weapons capabilities. The site, built clandestinely, was first publicly acknowledged in 2009. Fordo is buried deep in the mountains of northern Iran, and US President Donald Trump is reportedly considering dropping a bunker-busting bomb to destroy the heavily fortified facility. The site's location deep below ground means that in the immediate aftermath, 'the likelihood of significant contamination [in the surrounding region] is significantly reduced, if not zero,' Bennett said. Over time, though, radioactive isotopes would be 'leaching into the groundwater,' he added. That means it will be critical that Iran allows the IAEA into the country to help manage any leaks – similarly to how the agency assists at the Chernobyl site in Ukraine, decommissioning and managing radioactive waste, Bennett said. It's not yet clear whether Iran will do so. One week into the conflict, it is still escalating. 'At this point, given the fog of war… everything is conjecture,' Bennett said. A new at-home spit test appears to be as effective as birth control pills at preventing pregnancy – and it will soon roll out across Europe, Euronews Health has learned. The device from Inne, a Berlin-based women's health tech company, has been available for years as a fertility-monitoring tool designed to help people boost their chances of pregnancy. Called Minilab, it works by tracking users' progesterone, the sex hormone that plays a role in fertility, via daily changes in their saliva. Now, Minilab can also be used to prevent pregnancy, after a small study showed the device was 92 per cent effective – about on par with birth control pills, but without any of the side effects. 'Progesterone can be used for conception or contraception,' Eirini Rapti, Inne's chief executive and founder, told Euronews Health in an exclusive interview. But 'there was no reliable saliva testing' on the market, she said. So Rapti and her team decided to create it themselves. The British Standards Institution, which reviews medical device manufacturers in Europe, certified Inne's Minilab this month, meaning it can now be sold as a contraceptive device as well as a fertility tracker. Inne plans to roll out the device in the European Union in September, with sales in the United Kingdom to follow. The device is part of a new wave of women's health apps that have gained steam in recent years by infusing tech into fertility awareness, in a bid to make these contraceptive methods more effective, scientifically rigorous, and personalised. Key competitors like Natural Cycles – which, in 2017, became the EU's first certified contraceptive app – rely on temperature readings to track hormonal levels. But Rapti said saliva, as 'hardcore biological data,' is more accurate because it isn't affected by, for example, having a fever or working up a sweat. Meanwhile, blood tests are considered the gold standard for hormone tracking, but some research indicates saliva could be a promising alternative because it is cheaper, faster, and can be done easily at home. The Minilab device is fairly easy to use. Around the same time each day, the user spits into a test strip and inserts it into a small, sleek device that measures their progesterone. That data feeds back into an app, which learns about their hormonal fluctuations over time. That allows it to identify their fertile window, or the approximately six days per month when they are most likely to get pregnant. 'It's similar technology to COVID tests with antibodies, or pregnancy tests,' Rapti said. In the company's observational study, more than 200 women in Germany used the Minilab for six months. They were advised not to have unprotected sex on days the app said they were fertile, and asked to record their sexual activity. Eleven women got pregnant, but two were excluded from the analysis for violating the study guidelines. Others had unprotected sex on days the app identified as high risk for pregnancy, Rapti said. 'We did not have a case where our system gave the wrong ovulation day, or the wrong fertile day,' Rapti said. The findings translate to an effectiveness rate of 92 per cent, meaning that if 100 women used the Minilab as a contraceptive for one year, eight could expect to become pregnant. That's about the same as birth control pills or the contraceptive patch, and more effective than condoms (82 per cent). But it's far less effective than non-hormonal intrauterine devices (IUDs), sometimes called copper coils (more than 99 per cent). Notably, the study – which has not yet been published in a peer-reviewed, academic journal – did not include a control or comparison group, so Inne can't definitively prove that the device is what prevented pregnancy. Other methods of birth control have also been researched for decades, which means it can be difficult to directly compare Inne's results. But if the findings hold up over longer periods of time and with larger groups of people, it would make Minilab equally effective as Natural Cycles, the only other app-based contraceptive on the European market. The approach is also not for everyone. Women should not use Minilab if they have irregular menstrual cycles or were pregnant or breastfeeding within the past three months, the company said. It said women interested in switching from a hormonal contraceptive – such as birth control pills or certain IUDs – should wait at least two months before starting Minilab to allow their hormones to return to natural levels. Minilab already has thousands of users in Germany, Austria, and Switzerland, Rapti said. Eventually, she hopes to add testing for cortisol – the stress hormone – as well as testosterone and vitamins, to help women track their health throughout their lives, not only around pregnancy. 'If you have three or four years of data,' Rapti said, 'you can really start building some intelligence'.

France 24

2 days ago

• France 24

US approves Gilead's twice-yearly injection to prevent HIV

Drugs to prevent HIV transmission, known as pre-exposure prophylaxis or PrEP, have existed for more than a decade. But because they typically require taking a daily pill, they have struggled to make a significant dent in global infections. "This is a historic day in the decades-long fight against HIV," said Daniel O'Day, Gilead's chairman and chief executive officer, in a statement. Lenacapavir, marketed under the brand name Yeztugo, has been shown in clinical trials to reduce the risk of HIV transmission by more than 99.9 percent in adults and adolescents -- making it functionally akin to a powerful vaccine. But optimism may be tempered by the drug's expected eye-watering price tag. While the company has not disclosed specifics, analysts estimate the US launch price could be as high as $25,000 per year. Activists are calling for the price to be slashed to $25 per person annually to help end the HIV pandemic. The approval also comes as President Donald Trump's administration has slashed funding for HIV treatment and prevention programs both overseas and within the United States.